… The duration of hospitalization reported in the control group in the present study (median =
… stay of COVID-19 patients mainly in China (median = 14 days). The present study showed …

… in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine … WI)
[17,18,19,20]. In this multi-center observational cohort study we report progression from mildly …

… Long COVID diagnosis from a medical provider was a pre-specified secondary outcome …
days after randomization and confirmed in medical records. Findings: Of 1323 randomized trial …

… The present randomized trial also found that ruxolitinib with SoC treatment was well tolerated
with low hematological and nonhematological toxicities. All ruxolitinib recipients completed …

… treatment for early COVID-19. Multiple repurposed drugs have shown promise in treating
COVID-19. … different repurposed drugs as treatments for early COVID-19 among outpatients at a …

… a randomized, two-arm, controlled, multi-center trial to evaluate the efficacy and safety of
COVID-19 HIG in patients who were hospitalized with moderate-severe COVID-19 infection. …

… randomized, controlled trial to assess the efficacy of combining hydroxychloroquine and
favipiravir plus standard of care in patients with moderate-to-severe COVID-19… , randomized trial. …

… of participants in the multi-center, open-label, randomized clinical trial and the … -randomized
study of HCQ treatment for COVID-19 was conducted in France [15]. Gautret et al. treated 20 …

… conducted a multi-center, randomized clinical trial in patients hospitalized for COVID-19. All
… During the COVID-19 pandemic, the acute need for medical treatments has spread the use …

… COVID-19 patients. We attempted to verify the effectiveness and safety of tocilizumab therapy
in COVID-19 and identify patients most likely to benefit from this treatment. We conducted a …